Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence Of Pancreatic Cancer Emerges as a Core Driver of the Pancreatic Cancer Diagnostic Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate (CAGR) of 7.2%. The prior growth was fueled by factors including advancements in molecular and genomic profiling, developments in chemotherapy, improvements in radiation therapy, research focused on pancreatic cancer genetics, awareness movements, and initiatives for early detection.

What's the Projected Size of the Global Pancreatic Cancer Diagnostic Market by 2029?
In the coming years, we expect to witness a robust expansion in the market size of pancreatic cancer diagnostics, which is projected to reach $6.38 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%. The projected growth within this forecasted period can largely be linked to advancements in liquid biopsy, targeted therapies, the use of artificial intelligence in diagnosis, tailored medical treatments, early detection biomarkers, and neoadjuvant therapies. Some predominant trends during this period would be intensive research in immunotherapy, strides in imaging technology, surgical breakthroughs, global cooperation in research initiatives, and the incorporation of big data analytics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Top Growth Drivers in the Pancreatic Cancer Diagnostic Industry: What's Accelerating the Market?
The escalation of pancreatic cancer prevalence is anticipated to drive the expansion of the pancreatic cancer diagnostic market. Pancreatic cancer is a disease where the pancreatic tissues generate cancerous cells. Factors like smoking, diabetes, chronic pancreatitis, familial history of pancreatic cancer, pancreatic inflammation, and certain genetic conditions are primarily responsible for the increased rate of pancreatic cancer. The diagnosis is vital in pancreatic cancer as it aids in shaping treatment options, specifying the cancer stage, identifying tumor characteristics, and devising treatment strategies to enhance the results and provide better patient care. For instance, the United States' American Society of Clinical Oncology predicts that 64,050 individuals (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer in 2023. The disease ranks as the eighth most common cancer in women and tenth in men. The rate of new pancreatic cancer cases has grown around 1% annually in both genders. Consequently, the escalating prevalence of pancreatic cancer fuels the expansion of the pancreatic cancer diagnostic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11981&type=smp

What Trends Will Shape the Pancreatic Cancer Diagnostic Market Through 2029 and Beyond?
Emerging trends in the pancreatic cancer diagnostics market are largely centered on product innovations. To maintain their competitive edge, companies within this market are implementing innovative techniques. An example of this is the Singapore-based biopharmaceutical company, Prestige Biopharma Limited that, in March 2023, introduced a first-of-its-kind PAUF-detecting diagnostic kit. This kit serves as a crucial tool for early detection of pancreatic cancer as PAUF (Pancreatic Adenocarcinoma Upregulated Factor) is a distinct tumor-specific biomarker linked with early metastasis and excessive expression in roughly 80% of the cases of pancreatic cancer. The new diagnostic method provides high levels of accuracy and precision in identifying PAUF. Early research indicates that PAUF expression levels in pancreatic cancer patients' blood plasma is nearly 1.9 times more than in healthy individuals, according to data from Prestige Biopharma's Innovative Discovery Center.

What Are the Main Segments in the Pancreatic Cancer Diagnostic Market?
The pancreatic cancer diagnostic market covered in this report is segmented -

1) By Product: Instruments, Consumables, Services
2) By Treatment: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy
3) By Cancer Type: Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Colloid Carcinoma, Endocrine
4) By Test Type: Imaging Test, Biopsy, Blood Test, Genomic Test, Other Test Types
5) By End-User: Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Instruments: Imaging Systems, Biopsy Devices, Endoscopy Equipment
2) By Consumables: Reagents, Biopsy Needles, Assay Kits
3) By Services: Diagnostic Testing Services, Laboratory Services, Consulting Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11981&type=smp

Which Top Companies are Driving Growth in the Pancreatic Cancer Diagnostic Market?
Major companies operating in the pancreatic cancer diagnostic market include Pfizer Inc., Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healare GmbH, FUJIFILM Corporation, Becton inson and Company, Koninklijke Philips N.V., GE Healare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation

Which Regions Will Dominate the Pancreatic Cancer Diagnostic Market Through 2029?
North America was the largest region in the pancreatic cancer diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11981

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.